Quantcast

Latest Tissue plasminogen activator Stories

2014-08-08 10:47:23

The Lancet Reduces long-term disability, even in older people and in those with the most severe stroke Many more stroke patients could benefit from thrombolytic treatment (the use of drugs to break up or dissolve blood clots), but it needs to be administered as quickly as possible after the first signs of illness, according to new findings from the largest meta-analysis to date investigating the clot-busting drug alteplase. The study, which involved more than 6700 stroke patients, is...

2014-08-04 16:26:50

Placement Agent Spencer Trask Ventures Rallies investors to "Take Stock in Stroke" NEW YORK, Aug. 4, 2014 /PRNewswire/ -- Vesselon, Inc. is a development stage company that is creating one of the world's first portable devices for the immediate treatment of ischemic stroke -- the most common type of stroke affecting 87% of patients. Vesselon has engaged private investment firm Spencer Trask Ventures, Inc. as its placement agent to market a private preferred round to facilitate...

2014-06-04 12:28:51

HOUSTON, June 4, 2014 /PRNewswire-USNewswire/ -- The University of Texas Health Science Center at Houston (UTHealth) Medical School, in partnership with Memorial Hermann-Texas Medical Center (TMC), is proud to announce that the UTHealth Mobile Stroke Unit has successfully transported and helped save the life of its very first patient. http://photos.prnewswire.com/prnvar/20140603/94043 The unit, which is the first and only of its kind in the nation treating patients, is a...

2014-06-02 08:30:20

REHOVOT, Israel, June 2, 2014 /PRNewswire/ -- D-Pharm Ltd. (TASE: DPRM), Rehovot, Israel, reports today, June 2nd, 2014, the interim results for the second dose tier of stroke patients that completed follow-up in its Phase 2 clinical study of THR-18 and confirms the tolerability of THR-18 at a dose of 0.54 mg/kg, administered together with tissue plasminogen activator (tPA) in acute ischemic stroke (AIS) patients. The primary goal of the current study is to identify the...

2014-04-24 23:09:00

UVA's stroke program has received the highest quality award from the American Heart Association. Charlottesville,VA (PRWEB) April 24, 2014 The American Heart Association has recognized the quality and safety of UVA’s stroke care with two awards. UVA received both the Get With The Guidelines®-Stroke Gold-Plus Quality Achievement Award and made the Target: Stroke Honor Roll. The awards represent the highest level of stroke quality recognition offered by the AHA. “We couldn’t...

2014-04-23 09:46:08

Study finds jump in patients receiving clot-busting drug within 'golden hour' Administering a clot-dissolving drug to stroke victims quickly — ideally within the first 60 minutes after they arrive at a hospital emergency room — is crucial to saving their lives, preserving their brain function and reducing disability. Given intravenously, tPA (tissue plasminogen activator) is currently the only Food and Drug Administration–approved therapy shown to improve outcomes for patients...

2014-04-23 09:40:01

Using an ambulance that included a computed tomography (CT) scanner, point-of-care laboratory, telemedicine connection and a specialized prehospital stroke team resulted in decreased time to treatment for ischemic stroke, according to a study in the April 23/30 issue of JAMA, a neurology theme issue. Stroke is a leading cause of death and disability. In acute ischemic stroke, thrombolysis (dissolving of blood clots) using intravenous tissue plasminogen activator (tPA) is the treatment of...

2014-04-23 09:33:59

In a study that included more than 71,000 stroke patients, implementation of a quality initiative was associated with improvement in the time to treatment and a lower risk of in-hospital death, intracranial hemorrhage (bleeding in the brain), and an increase in the portion of patients discharged to their home, according to the study appearing in the April 23/30 issue of JAMA, a neurology theme issue. Intravenous tissue plasminogen activator (tPA; an enzyme that helps dissolve clots)...

2014-03-04 08:32:11

REHOVOT, Israel, March 4, 2014 /PRNewswire/ -- D-Pharm Ltd (TASE: DPRM) announced today, March 4th, 2014, the successful interim analysis of the first group of stroke patients that completed follow-up in the Phase 2 clinical study of THR-18. The interim report confirms the safety and tolerability of THR-18 at a dose of 0.18mg/kg, administered together with tissue plasminogen activator (tPA) in acute ischemic stroke patients. The interim report gives a green light to proceed to...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related